EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), patients with NSCLC characterized by activating mutations in the epidermal growth factor receptor (EGFR) clearly benefit from EGFR–tyrosine kinase inhibitor (TKI) therapy.